share_log

丽珠集团获华福证券买入评级，创新+高壁垒制剂齐头并进

JRJ Finance ·  May 13 14:58

5月13日，丽珠集团获华福证券买入评级，近一个月丽珠集团获得2份研报关注。

研报预计公司2024-2026归母净利润分别为22/25.2/28.2亿元，同比增长13%/14%/12%。研报认为，公司基本盘稳固，创新管线丰富，是国内仿转创的龙头企业。

风险提示：行业政策变化风险、产品降价风险、新药研发风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment